Prostate cancer (PCa) is a slow, progressive disease.
Prostate specific antigen testing, screening, and aggressive case identification has made PCa the most frequently diagnosed cancer. Concerns regarding overdiagnosis and overtreatment flourish on a large scale. In order to avoid overtreatment for those in whom therapeutic intervention is not required, active surveillance for eligible patients with the use of 5-alpha reductase can be considered a safe and a promising approach to delay the progression of the disease with minimal side effects.
Al Edwan G, Fleshner N. Are you the author?
Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. Ghazi.email@example.com
Reference: Curr Urol Rep. 2013 Apr 12. Epub ahead of print.
UroToday.com Prostate Cancer Section